Susan M. Flint
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Susan M. Flint
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 16 | |
| Public Company | Medical Specialties | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Susan M. Flint tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact Director/Board Member Chief Tech/Sci/R&D Officer | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Consultant / Advisor Founder Private Equity Investor Private Equity Analyst | |
| SPRUCE BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| IMAGO BIOSCIENCES, INC. | Biotechnology | Founder Director/Board Member | |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
HealthCap Advisor AB
 HealthCap Advisor AB Investment ManagersFinance HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden. | Investment Managers | Director/Board Member Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
| NUCANA PLC | Biotechnology | Chairman Director/Board Member | |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Uppsala | College/University | Doctorate Degree Graduate Degree | |
Anjarium Biosciences AG
 Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Pharmaceuticals: Major | Chairman | |
| ALDEYRA THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Altimmune UK Ltd.
 Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
| ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Director/Board Member | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
SmithKline Beecham Ltd.
 SmithKline Beecham Ltd. Pharmaceuticals: MajorHealth Technology Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TREVI THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| ALLENA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
FluGen, Inc.
 FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | Pharmaceuticals: Major | Director/Board Member | |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Pharmaceuticals: Major | Director/Board Member | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Chairman | |
| The University of Edinburgh | College/University | Doctorate Degree | |
| Pasteur Merieux MSD Ltd. | President | ||
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Biotechnology | Chief Executive Officer | |
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Biotechnology | Director/Board Member | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The Johns Hopkins University | College/University | Doctorate Degree | |
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
Top Institute Pharma
 Top Institute Pharma BiotechnologyHealth Technology Part of Center for Translational Molecular Medicine, Top Institute Pharma provides pharmaceutical research services. The company is based in Leiden, Netherlands. Top Institute Pharma was acquired by Center for Translational Molecular Medicine on June 09, 2015. | Biotechnology | Director/Board Member | |
| CANTARGIA AB | Pharmaceuticals: Major | Director/Board Member | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director of Finance/CFO | |
| Lisa Martin-Löf Konsultbyrå AB | Director/Board Member | ||
| Oncopeptides Incentive AB | Director/Board Member | ||
| University of Stockholm | College/University | Undergraduate Degree | |
| BIOARCTIC AB | Pharmaceuticals: Major | Director of Finance/CFO | |
A3P Biomedical AB
 A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Medical/Nursing Services | Director of Finance/CFO | |
| University of Utrecht | College/University | Doctorate Degree | |
| Organon International BV | President |
Statistiche
Distribuzione geografica
| Stati Uniti | 22 |
| Svezia | 16 |
| Regno Unito | 10 |
| Paesi Bassi | 5 |
| Svizzera | 2 |
Settori
| Health Technology | 34 |
| Consumer Services | 8 |
| Finance | 3 |
| Commercial Services | 3 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 143 |
| Corporate Officer/Principal | 32 |
| Chairman | 30 |
| Independent Dir/Board Member | 27 |
| Chief Tech/Sci/R&D Officer | 18 |
Contatti più connessi
| Insiders | |
|---|---|
| Björn Ingemar Odlander | 53 |
| Dina Chaya | 23 |
| Johannes G. C. P. Schikan | 22 |
| Hugh Young Rienhoff | 21 |
| Marten Steen | 21 |
| David J. Clark | 21 |
| Bali Muralidhar | 20 |
| Anders Martin-Löf | 16 |
| Peder Sven Walberg | 15 |
| Andrew Kay | 14 |
| Birgitte Volck | 13 |
| Jonas Karl Hansson | 13 |
| Richard M. Thorn | 7 |
| Rick Lilley | 7 |
| Carl Bjartmar | 5 |
- Borsa valori
- Insiders
- Susan M. Flint
- Connessioni Società
